Xarelto上市后价格

Rivaroxaban (Xarelto) is produced by Bayer Healthcare Co., Ltd. Its main clinical indications are: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban (Xarelto, Xarelto) post-market price: United States: Strength: 10mg-10 tablets/box, pharmacy price: US$156.24; Strength: 15mg-30 tablets/box, pharmacy price: US$438.67; Strength: 20mg-30 tablets/box, pharmacy price: US$553.65. China: Domestic rivaroxaban (Xarelto) is an original drug produced by Bayer Pharma AG/Germany Bayer Pharmaceuticals. Specification: 10mg-5 tablets/box, priced at about 138$; Specification: 15mg-7 tablets/box, priced at about 199$; Specification: 20mg-7 tablets/box, priced at about 263$.  

Common adverse reactions of rivaroxaban (Xarelto, Xarelto) include nausea, increased GGT and increased aminotransferases. Adverse effects should be explained in the context of surgery. Due to its pharmacological mode of action, rivaroxaban (Xarelto) may cause an increased risk of latent or overt bleeding in some tissues or organs, possibly resulting in posthemorrhagic anemia. The signs, symptoms, and severity of bleeding (including possible fatal consequences) will vary depending on the location, extent, or extent of the bleeding. The risk of bleeding may be increased in certain patient groups, such as patients with uncontrolled severe arterial hypertension and/or patients receiving concomitant medications that affect hemostasis. Hemorrhagic complications may manifest as weakness, weakness, pallor, dizziness, headache, or unexplained swelling. Therefore, the potential for bleeding should be considered when evaluating patients taking rivaroxaban (Xarelto).